CereScan and Molecular Imaging of Colorado Add TRICARE to Approved Insurers

Share Article

CereScan Corp., the national leader in providing statistically measured brain diagnostics and molecular imaging, and its subsidiary Molecular Imaging of Colorado, is now accepting TRICARE military insurance as an in-network provider.

CereScan Corp. and its wholly-owned subsidiary, Molecular Imaging of Colorado, have been approved by TRICARE, the health care insurance provider of the United States Department of Defense Military Health System. TRICARE provides health benefits for active-duty military members, retirees, and their families.

“Serving the needs of our nation’s military population has been a long-term objective of CereScan,” said John Kelley, Chairman and CEO of CereScan Corp. “Being able to provide our imaging services to the military and their families signals our commitment to helping both active duty and veterans with the most important first step, the correct diagnosis. By achieving this vital first step, our expert physicians are able to help these men and women get better, quicker, through collaboration with their treating doctors.”

Traumatic brain injuries and PTSD are two of the most common diagnoses soldiers receive after returning from battle. Although an estimated 10-20% of veterans experience some form of traumatic brain injury, only a small fraction receive proper diagnosis and treatment.

For many veterans who are experiencing one or both of these debilitating disorders, following the best course of treatment is difficult without an accurate diagnosis. That’s where CereScan makes all the difference. CereScan’s SPECT imaging technology goes beyond traditional diagnostic tools to review cerebral blood flow and cellular processes that help accurately diagnose traumatic brain injuries, helping physicians and patients create an effective treatment plan.

“Our research through the ‘Invisible Brain Injury Project’, as well as other outreach efforts related to understanding and treating their wounds of war, particularly as it relates to chronic Traumatic Brain Injury, is indicative of our commitment to them,” Kelley added “The addition of TRICARE to our list of insurers provides greater opportunity to assist those most in need.”

Molecular Imaging of Colorado (MIC) is based in Littleton, Colorado and is a wholly-owned subsidiary of CereScan. MIC offers PET/CT imaging services to the patients of Oncologists, Pulmonologists, and Urologists and any others who may need diagnostic imaging. To schedule an appointment or for more information, please call 303-954-4957.

CereScan is the nation’s leader in providing statistically measured brain diagnostics based on a new generation of imaging software, PET/CT (Positron Emission Tomography/Computed Tomography) and SPECT (Single Photon Emission Computed Tomography) neuroimaging technologies. Referring and treating medical experts can rely on CereScan to offer differentiated diagnoses on a wide array of brain-based disorders including:

  •     Traumatic Brain Injury
  •     Toxic Brain Injury
  •     Alzheimer’s Disease
  •     Mild Cognitive Impairment
  •     Other Dementias
  •     Parkinson’s Disease
  •     Obsessive Compulsive Disorder
  •     Bipolar Disorder
  •     ADD/ADHD
  •     Anxiety Disorder

About CereScan

CereScan combines state-of-the-art SPECT and PET/CT brain imaging technologies with a patient centered model of care to provide the highest level of neurodiagnostics anywhere. Using quantitative functional brain imaging, advanced imaging software, and an extensive library of clinical data, the CereScan medical team provides physicians with unmatched objective diagnostic information. CereScan helps patients and their physicians better understand the neurological basis of their conditions. In a variety of legal settings, CereScan provides objective evidence to attorneys and their clients regarding traumatic and toxic brain injuries. For researchers, CereScan provides independent pre- and post-treatment measures of organic changes in the brain along with measures of symptoms related to the brain disorder of interest. For more information, please call (866) 722-4806 or visit http://www.CereScan.com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

John Kelley

Gail McClurg
@CereScan
Follow >